Aduro Biotech | Discovering and Developing Immunotherapies.

Immunotherapy

Learn how immunotherapies harness a person’s immune system to fight diseases

STING Pathway

APRIL Pathway

Clinical Trials

Learn more about Aduro’s clinical programs

Investors

Download the 2018 Annual Report

Recent News

November 08, 2019 Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting

November 07, 2019 Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results

October 02, 2019 Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

Careers

Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?